
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
}Drug costs continue to rise at an alarming rate. Two major reasons for the increasing costs are introductions of new drugs and direct-to-consumer advertising campaigns that have been effective in marketing expensive name brand drugs.}
over 25 years ago
Research: New Horizonsover 25 years ago
Earnings: Tough Times Aheadover 25 years ago
Outbreak: Anthrax Alarmover 25 years ago
Patents: China on the Genome Mapover 25 years ago
Privacy, Pediatrics, and Policyover 25 years ago
Lilly's International Familyover 25 years ago
Update: Punishment and Reprieveover 25 years ago
Shortage: Vaccine Worriesover 25 years ago
Gateway to Japan





